Agile Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Agile Therapeutics, Inc.‘s stocks are currently a part of 32 hedge funds’ portfolios, which represents 41.78% of the total amount of its stocks outstanding. This makes up a total of 1.01M shares of Agile Therapeutics, Inc.. Compared to the previous quarter, the number grew by 7.71% or 72.55K shares more. As for the holding position changes, 37.5% (12) of current hedge fund investors increased the number of shares held, 18.75% (6) of current holders sold a part of the shares held, and 50% (16) closed the holdings completely. 4 hedge funds are new holders of Agile Therapeutics, Inc. stock in Q1 2022, it is 12.5% of total holders.
Hedge funds holding Agile Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 45 |
|---|---|
| Q3 2017 | 48 |
| Q4 2017 | 50 |
| Q1 2018 | 47 |
| Q2 2018 | 38 |
| Q3 2018 | 28 |
| Q4 2018 | 26 |
| Q1 2019 | 27 |
| Q2 2019 | 26 |
| Q3 2019 | 35 |
| Q4 2019 | 49 |
| Q1 2020 | 65 |
| Q2 2020 | 80 |
| Q3 2020 | 80 |
| Q4 2020 | 80 |
| Q1 2021 | 75 |
| Q2 2021 | 67 |
| Q3 2021 | 49 |
| Q4 2021 | 45 |
| Q1 2022 | 32 |
Hedge funds changes in Agile Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 11 | 9 | 15 | 17 | -7 |
|---|---|---|---|---|---|
| Q3 2017 | 13 | 12 | 9 | 9 | 5 |
| Q4 2017 | 14 | 18 | 9 | 12 | -3 |
| Q1 2018 | 6 | 14 | 16 | 9 | 2 |
| Q2 2018 | 6 | 9 | 10 | 15 | -2 |
| Q3 2018 | 7 | 5 | 5 | 17 | -6 |
| Q4 2018 | 5 | 4 | 7 | 6 | 4 |
| Q1 2019 | 5 | 7 | 7 | 4 | 4 |
| Q2 2019 | 2 | 7 | 2 | 3 | 12 |
| Q3 2019 | 15 | 7 | 4 | 5 | 4 |
| Q4 2019 | 27 | 11 | 4 | 13 | -6 |
| Q1 2020 | 31 | 17 | 10 | 12 | -5 |
| Q2 2020 | 32 | 28 | 9 | 17 | -6 |
| Q3 2020 | 13 | 20 | 31 | 14 | 2 |
| Q4 2020 | 10 | 28 | 17 | 12 | 13 |
| Q1 2021 | 12 | 19 | 26 | 17 | 1 |
| Q2 2021 | 18 | 15 | 23 | 26 | -15 |
| Q3 2021 | 1 | 10 | 22 | 19 | -3 |
| Q4 2021 | 10 | 12 | 12 | 14 | -3 |
| Q1 2022 | 4 | 12 | 6 | 16 | -6 |
Hedge funds changes in Agile Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 57,000 | 0 |
| Q4 2017 | 288,000 | 16,000 |
| Q1 2018 | 40,000 | 1,000 |
| Q2 2018 | 0 | 0 |
| Q3 2018 | 1,000 | 0 |
| Q4 2018 | 87,000 | 0 |
| Q1 2019 | 386,000 | 2,000 |
| Q2 2019 | 217,000 | 0 |
| Q3 2019 | 61,000 | 0 |
| Q4 2019 | 758,000 | 389,000 |
| Q1 2020 | 1,028,000 | 294,000 |
| Q2 2020 | 1,534,000 | 497,000 |
| Q3 2020 | 1,455,000 | 388,000 |
| Q4 2020 | 641,000 | 214,000 |
| Q1 2021 | 1,433,000 | 275,000 |
| Q2 2021 | 584,000 | 151,000 |
| Q3 2021 | 363,000 | 48,000 |
| Q4 2021 | 177,000 | 0 |
| Q1 2022 | 50,000 | 0 |